
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Agenus Inc (AGEN)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: AGEN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Year Target Price $11.5
Year Target Price $11.5
1 | Strong Buy |
1 | Buy |
3 | Hold |
0 | Under performing |
0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.8% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 130.50M USD | Price to earnings Ratio 0.16 | 1Y Target Price 11.5 |
Price to earnings Ratio 0.16 | 1Y Target Price 11.5 | ||
Volume (30-day avg) 5 | Beta 1.43 | 52 Weeks Range 1.38 - 18.74 | Updated Date 06/29/2025 |
52 Weeks Range 1.38 - 18.74 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 29.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -191.5% | Operating Margin (TTM) -55.31% |
Management Effectiveness
Return on Assets (TTM) -28.7% | Return on Equity (TTM) -1278.83% |
Valuation
Trailing PE 0.16 | Forward PE 2.82 | Enterprise Value 204059206 | Price to Sales(TTM) 1.31 |
Enterprise Value 204059206 | Price to Sales(TTM) 1.31 | ||
Enterprise Value to Revenue 2.05 | Enterprise Value to EBITDA -2.42 | Shares Outstanding 27416800 | Shares Floating 27014645 |
Shares Outstanding 27416800 | Shares Floating 27014645 | ||
Percent Insiders 1.44 | Percent Institutions 34.04 |
Analyst Ratings
Rating 3 | Target Price 11.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Agenus Inc

Company Overview
History and Background
Agenus Inc., founded in 1994 (originally Antigenics), is a biopharmaceutical company focused on developing and commercializing immunotherapies to treat cancer. It initially focused on heat shock protein-based vaccines and has evolved to focus on checkpoint modulators, cell therapies, and other immunotherapeutic approaches.
Core Business Areas
- Checkpoint Modulators: Agenus develops and commercializes antibodies that target immune checkpoints, such as CTLA-4 and PD-1, to enhance the body's anti-cancer immune response.
- Cell Therapies: Agenus is engaged in the discovery and development of adoptive cell therapies, including T-cell therapies, to target and eliminate cancer cells.
- Vaccines: Agenus is exploring vaccine strategies to prime the immune system to recognize and attack cancer cells. Includes programs using QS-21 Stimulon adjuvant.
Leadership and Structure
The leadership team includes Garo H. Armen as Chairman and CEO. The company is structured around research & development, clinical development, and commercialization functions.
Top Products and Market Share
Key Offerings
- BALSTICALI (zalifrelimab-zlfg): A PD-1 blocking antibody approved for relapsed or metastatic cervical cancer in combination with chemotherapy. Agenus has partnered with Betta Pharmaceuticals for the Chinese market. Competitors include Keytruda (Merck), Opdivo (Bristol Myers Squibb), and Libtayo (Regeneron/Sanofi). Market share data is still evolving; however, Keytruda and Opdivo hold the majority of the PD-1 inhibitor market.
- AGEN1181: AGEN1181 is a next-generation anti-CTLA-4 antibody designed to enhance anti-tumor activity while minimizing toxicity. Currently in clinical trials for various cancers. Competitors include Yervoy (Bristol Myers Squibb). No specific market share data is available yet as it is still under development.
- QS-21 Stimulon adjuvant: A saponin-based vaccine adjuvant. Agenus has partnered with various companies for vaccines against different diseases. Competitors are dependent on the vaccine programs using this adjuvant. No significant revenue is publicly available for Agenusu2019s QS-21.
Market Dynamics
Industry Overview
The immunotherapy market is experiencing substantial growth, driven by the increasing prevalence of cancer and the clinical success of immunotherapeutic agents like checkpoint inhibitors and cell therapies. The market is competitive, with both established pharmaceutical companies and emerging biotech firms.
Positioning
Agenus is positioned as an innovative immunotherapy company with a focus on developing novel checkpoint modulators, cell therapies, and vaccine adjuvants. Its competitive advantage lies in its discovery platforms and proprietary technologies, although its current market share is small compared to larger pharmaceutical companies.
Total Addressable Market (TAM)
The global immunotherapy market is projected to reach hundreds of billions of dollars annually. Agenus is positioned to capture a share of this market through its pipeline of clinical and preclinical assets.
Upturn SWOT Analysis
Strengths
- Innovative immunotherapy pipeline
- Proprietary discovery platforms
- Experienced leadership team
- Strategic partnerships
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial success
- Competition from established players
- History of net losses
Opportunities
- Expanding immunotherapy market
- Potential for new drug approvals
- Strategic collaborations and licensing agreements
- Advancements in cell therapy and vaccine technologies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other immunotherapy companies
- Patent expirations
Competitors and Market Share
Key Competitors
- MRK
- BMY
- REGN
- AZN
Competitive Landscape
Agenus faces intense competition from larger pharmaceutical companies with established immunotherapy franchises. Agenus's advantages include its innovative pipeline and proprietary technologies. Its disadvantages include limited financial resources and a smaller commercial infrastructure.
Major Acquisitions
4-Antibody AG
- Year: 2014
- Acquisition Price (USD millions): 15
- Strategic Rationale: Expanded antibody discovery capabilities and strengthened the company's pipeline of immuno-oncology candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by strategic collaborations and advancements in the company's pipeline. The company's success has been limited by the fact that the company has been in a net loss position for years.
Future Projections: Future growth is contingent on the success of clinical trials, regulatory approvals, and commercialization of its immunotherapy products. Analyst estimates are based on assumptions about the potential of Agenus's pipeline.
Recent Initiatives: Recent initiatives include advancing clinical trials for its checkpoint modulators and cell therapies, expanding partnerships, and seeking regulatory approvals for its lead product candidates.
Summary
Agenus Inc. is an immunotherapy company with innovative research, facing significant hurdles. Positive clinical trial data and strategic collaborations are driving forces. Limited financial resources and intense competition are key challenges. Its success depends on successfully navigating the regulatory landscape and commercializing its pipeline. The company is in an early stage of growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q)
- Company press releases
- Analyst reports
- Industry reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data and market information are subject to change. The AI-based rating is a general assessment and should not be the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Agenus Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2000-02-04 | Founder, Executive Chairman & CEO Dr. Garo H. Armen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 316 | Website https://www.agenusbio.com |
Full time employees 316 | Website https://www.agenusbio.com |
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.